Ibrutinib and Venetoclax Combo ' Impressive ' in Front-Line CLL Ibrutinib and Venetoclax Combo ' Impressive ' in Front-Line CLL

The combination of ibrutinib and venetoclax has shown ' impressive results ' in the front-line treatment of chronic lymphocytic leukemia (CLL), and may not need to be continued indefinitely.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news